Sartorius Stedim Biotech presents Virosart Media
Virosart Media family: first risk-mitigating virus-retentive filters for cell culture media
Offers a fast and cost-effective solution for manufacturers to reduce the risk of virus contamination resulting from raw materials during fermentation.
Sartorius Stedim Biotech (SSB) has launched Virosart Media for virus retention in cell culture media. With this new media filter, the company offers a fast and cost-effective solution for manufacturers to reduce the risk of virus contamination resulting from raw materials, such as chemically defined media, during fermentation.
Virosart Media is a single-use filter that provides the highest level of safety for customers’ upstream processes as it is qualified for > 4 log10 reduction of small, non-enveloped viruses (e.g., MVM) and as a mycoplasma and leptospira retentive filter.
A major benefit of this new filter is that mid-scale and process filters of the Virosart Media product family will also be qualified as a sterile filter based on the current ASTM guideline. The first product of the Virosart Media family is a lab filter with a filtration area of 5.0 cm2 for down-scale, flow and capacity studies. The mid-scale filter with 0.29 m² and the process filters with 1 m² and 3 m² will follow in the second half of 2016.
Providing superior filter capacity for cell culture media and high patient safety is one of the biggest challenges in today’s upstream processing. ”In the past, downstream virus filters have been used in upstream processing as there were no other adequate solutions available. Our new membrane filter Virosart Media finally closes this gap in the market,” stated Birte Kleindienst, expert for viral clearance at Sartorius Stedim Biotech.
By launching Virosart Media filter, SSB rounds out customers’ individual risk mitigation strategy in upstream processing with an additional option: with the filters Sartopore 2 XLG (0.2 µm) for sterile filtration, Sartopore 2 XLM (0.1 µm) for retention of mycoplasma and with its new Virosart Media filter (20 nm) for virus retention, SSB enables customers to mitigate risk at three different levels.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.